175 related articles for article (PubMed ID: 35545406)
1. Relationship of PI3K-Akt/mTOR/AMPK signaling pathway genetic mutation with efficacy and prognosis in nasopharyngeal carcinoma.
Chen Y; He Q; Ma H; Zhang L; Liu F; Han Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Feb; 47(2):165-173. PubMed ID: 35545406
[TBL] [Abstract][Full Text] [Related]
2. Nasopharyngeal carcinoma with non-squamous phenotype may be a variant of nasopharyngeal squamous cell carcinoma after inhibition of EGFR/PI3K/AKT/mTOR pathway.
Wang J; Shang Y; Wang Y; Li Y; Wang L; Huang S; Lyu X
Histol Histopathol; 2024 May; 39(5):647-657. PubMed ID: 37971211
[TBL] [Abstract][Full Text] [Related]
3. APLNR is involved in ATRA-induced growth inhibition of nasopharyngeal carcinoma and may suppress EMT through PI3K-Akt-mTOR signaling.
Liu Y; Liu Q; Chen S; Liu Y; Huang Y; Chen P; Li X; Gao G; Xu K; Fan S; Zeng Z; Xiong W; Tan M; Li G; Zhang W
FASEB J; 2019 Nov; 33(11):11959-11972. PubMed ID: 31408612
[TBL] [Abstract][Full Text] [Related]
4. Genetic variations in the PI3K-PTEN-AKT-mTOR pathway are associated with distant metastasis in nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy.
Guo Q; Lu T; Chen Y; Su Y; Zheng Y; Chen Z; Chen C; Lin S; Pan J; Yuan X
Sci Rep; 2016 Nov; 6():37576. PubMed ID: 27876891
[TBL] [Abstract][Full Text] [Related]
5. Pre-treatment with angiotensin-(1-7) inhibits tumor growth via autophagy by downregulating PI3K/Akt/mTOR signaling in human nasopharyngeal carcinoma xenografts.
Lin YT; Wang HC; Chuang HC; Hsu YC; Yang MY; Chien CY
J Mol Med (Berl); 2018 Dec; 96(12):1407-1418. PubMed ID: 30374682
[TBL] [Abstract][Full Text] [Related]
6. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
7. Single-cell RNA sequencing reveals the mechanism of PI3K/AKT/mTOR signaling pathway activation in lung adenocarcinoma by KRAS mutation.
Xu L; Ding R; Song S; Liu J; Li J; Ju X; Ju B
J Gene Med; 2024 Jan; 26(1):e3658. PubMed ID: 38282149
[TBL] [Abstract][Full Text] [Related]
8. Activation of Akt/mTOR pathway is associated with poor prognosis of nasopharyngeal carcinoma.
Wang W; Wen Q; Xu L; Xie G; Li J; Luo J; Chu S; Shi L; Huang D; Li J; Fan S
PLoS One; 2014; 9(8):e106098. PubMed ID: 25165983
[TBL] [Abstract][Full Text] [Related]
9. PI3K-PKB-mTOR hyperactivation in relation to nasopharyngeal carcinoma progression and prognosis.
Yu JH; Chen L; Yu JY; Luo HQ; Wang L
J Cell Biochem; 2019 Jun; 120(6):10186-10194. PubMed ID: 30582216
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of lncRNA HAGLROS enhances the development of nasopharyngeal carcinoma via modulating miR-100/ATG14 axis-mediated PI3K/AKT/mTOR signals.
Zhang W; Zhang Y; Xi S
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3043-3052. PubMed ID: 31334669
[TBL] [Abstract][Full Text] [Related]
11. miR-3188 regulates nasopharyngeal carcinoma proliferation and chemosensitivity through a FOXO1-modulated positive feedback loop with mTOR-p-PI3K/AKT-c-JUN.
Zhao M; Luo R; Liu Y; Gao L; Fu Z; Fu Q; Luo X; Chen Y; Deng X; Liang Z; Li X; Cheng C; Liu Z; Fang W
Nat Commun; 2016 Apr; 7():11309. PubMed ID: 27095304
[TBL] [Abstract][Full Text] [Related]
12. C2orf40 inhibits metastasis and regulates chemo-resistance and radio-resistance of nasopharyngeal carcinoma cells by influencing cell cycle and activating the PI3K/AKT/mTOR signaling pathway.
Xie Z; Li W; Ai J; Xie J; Zhang X
J Transl Med; 2022 Jun; 20(1):264. PubMed ID: 35676661
[TBL] [Abstract][Full Text] [Related]
13. Correlation of the AKT/mTOR signaling pathway with the clinicopathological features and prognosis of nasopharyngeal carcinoma.
Wang Y; Sun J; Yao N
Eur J Histochem; 2021 Nov; 65(4):. PubMed ID: 34783234
[TBL] [Abstract][Full Text] [Related]
14. Ameliorative effects of Modified Huangqi Chifeng decoction on podocyte injury via autophagy mediated by PI3K/AKT/mTOR and AMPK/mTOR pathways.
Zhao M; Yin Y; Yang B; Chang M; Ma S; Shi X; Li Q; Li P; Zhang Y
J Ethnopharmacol; 2024 Mar; 321():117520. PubMed ID: 38042389
[TBL] [Abstract][Full Text] [Related]
15. The Expression and Prognostic Impact of the PI3K/AKT/mTOR Signaling Pathway in Advanced Esophageal Squamous Cell Carcinoma.
Wu N; Du Z; Zhu Y; Song Y; Pang L; Chen Z
Technol Cancer Res Treat; 2018 Jan; 17():1533033818758772. PubMed ID: 29463194
[TBL] [Abstract][Full Text] [Related]
16. The enhancement of Tetrandrine to gemcitabine-resistant PANC-1 cytochemical sensitivity involves the promotion of PI3K/Akt/mTOR-mediated apoptosis and AMPK-regulated autophagy.
Song J; Xu J; Guo J; Shang Y; Wang J; Wang T
Acta Histochem; 2021 Sep; 123(6):151769. PubMed ID: 34416437
[TBL] [Abstract][Full Text] [Related]
17. Lactoferrin mediates epithelial-mesenchymal transformation by regulating the PI3K/AKT/mTOR pathway to inhibit nasopharyngeal carcinoma metastasis.
Xu M; Fan Y; Zou G; Yang Q; Xu F
Cell Mol Biol (Noisy-le-grand); 2024 Mar; 70(3):130-135. PubMed ID: 38650146
[TBL] [Abstract][Full Text] [Related]
18. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT
Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725
[TBL] [Abstract][Full Text] [Related]
19. PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer.
Marquard FE; Jücker M
Biochem Pharmacol; 2020 Feb; 172():113729. PubMed ID: 31785230
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of Notch2 enhances radiosensitivity via inhibition of the AKT/mTOR signaling pathway in nasopharyngeal carcinoma.
Wu LZ; Huang ML; Qi CL; Shen LJ; Zou Y; Yang R; Sheng JF; Chen SM
Bioengineered; 2021 Dec; 12(1):3398-3409. PubMed ID: 34224316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
